Mobile website
Archive > Volume 24 Issue 12 > 2017,24(12):1350-1355. DOI:10.3872/j.issn.1007-385X.2017.12.002 Prev Next
Expert Forum
Current understanding of the role of T cell immunoglobulin and mucin-containing protein-3 in cancer immunity
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
The application of monoclonal antibodies to block immune checkpoints including PD-1, CTLA-4 has demonstrated a good efficacy in cancer immunotherapy. However, some patients poorly responded to these immune checkpoints blockers. One probable mechanism for this failure in igniting the antitumor effect was that other inhibitory molecules over expressed in these cases. As an immune checkpoint, T cell immunolobulin and mucin-containing protein-3(TIM-3) is widely expressed in a variety of immune cells, and palys an important role in the regulation of immune response. Many studies showed that lymphocytes from patient peripheral blood or tumor-infiltrating lymphocytes expressed high levels of TIM-3, which was associated with poor outcome. T cell, DC cell and mononuclear phagocytes with over-expressed TIM-3 showed significant inhibitory effects on antitumor immune response. In preclinical studies, combined blockade of TIM-3 and PD-1 with antibodies showed a synergistic effect on antitumor immunity. Clinical trials are underway to evaluate the safety and efficacy of TIM-3 monoclonal antibodies in cancer patients. However, the regulatory role of TIM-3 on immune cells has not been fully clarified, better understanding of the immune modulatory mechanism of TIM-3 helps to develop effective treatment strategy of blockade of TIM-3 in future clinical trials.
Keywords:
Project Supported:
Project supported by Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant (No. 201522119)
Clc Number:
